Blue Wolf Capital Partners LLC, a New York-based private equity firm, today announced it has entered into an agreement to acquire CIVCO Radiotherapy, a global leader of radiotherapy patient positioning and immobilization equipment, from Roper Technologies, Inc.

Getty Images


October 22, 2021 — Blue Wolf Capital Partners LLC, a New York-based private equity firm, today announced it has entered into an agreement to acquire CIVCO Radiotherapy, a global leader of radiotherapy patient positioning and immobilization equipment, from Roper Technologies, Inc. 

With a nearly 40-year operating history and a track record of quality and reliability, CIVCO Radiotherapy serves a blue-chip customer base of academic and community hospitals, cancer centers and OEM manufacturers. CIVCO Radiotherapy is headquartered in Iowa and operates globally in 90+ countries. 

Jeremy Kogler, Partner at Blue Wolf Capital, said, “We are incredibly pleased to partner with CIVCO Radiotherapy’s leadership team to further strengthen the company’s longstanding leading position in mission-critical radiotherapy products. We look forward to many years of continued growth at CIVCO Radiotherapy.” 

“We are pleased to have found a trusted partner in Blue Wolf with the skills, expertise and capital to support our significant growth goals and mission of improving outcomes for patients and healthcare providers worldwide,” said Nat Geissel, current President of CIVCO Radiotherapy, who will be named CEO of the company at transaction close. “Blue Wolf has a track record of successfully managing businesses. I’m confident their team will help to enhance our production capabilities and distribution efficiencies to meet the needs of patients and healthcare providers globally.”

“CIVCO Radiotherapy is a leader in the provision of radiotherapy positioning equipment,” said Shashank Patel, Principal at Blue Wolf Capital. “The company has a rich history of improving the patient experience and clinical outcomes for cancer patients globally. We believe CIVCO Radiotherapy is well positioned to further help clinicians offer more targeted and accurate treatment to patients as innovations in the radiotherapy space continue. We look forward to working with Nat and his team to build on its mission of improving outcomes and quality care for patients.”

The transaction is expected to close by the end of the year. Terms of the transaction were not disclosed.

For more information: www.civcort.com


Related Content

News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | Artificial Intelligence

July 26, 2024 — GE HealthCare and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, announced a strategic ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Digital Pathology

July 24, 2024 — Proscia, a developer of artificial intelligence (AI)-enabled digital pathology solutions for precision ...

Time July 24, 2024
arrow
Subscribe Now